Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial - Trial NCT03107078
Access comprehensive clinical trial information for NCT03107078 through Pure Global AI's free database. This Phase 4 trial is sponsored by Jie Shen and is currently status unknown. The study focuses on Thyroid Associated Ophthalmopathy. Target enrollment is 200 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Jie Shen
The Third Affiliated Hospital of Southern Medical University
Timeline & Enrollment
Phase 4
Oct 01, 2016
Oct 01, 2021
Primary Outcome
Number of patients defined as Response for the Glucocorticoids Treatment based on the 7 parameters of eye assessment,Number of patients defined as Deterioration for the Glucocorticoids Treatment based on the 7 parameters of eye assessment,Number of patients defined as Unchange for the Glucocorticoids Treatment based on the 7 parameters of eye assessment
Summary
For patients with active moderate-to-severe thyroid associated ophthalmopathy (TAO), the
 Intravenous Glucocorticoids (GCs) is the recommended therapy. However, the efficacy of GCs is
 not satisfied. Investigators established a novel classification of TAO for the first time to
 assess more precisely for better personal treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03107078
Non-Device Trial